Give Hope Blog
ASCO research highlights: First KRAS inhibitor and CAR T cell therapy for CLL
June 28, 2019 | City of Hope
At ASCO, City of Hope presented on a number of topics, but some of the most noteworthy involved the first KRAS inhibitor to show anti-tumor activity and the use of CAR T cell therapy in chronic lymphocytic leukemia.
Survivor Month: A second chance, thanks to CAR T trial
June 27, 2019 | Dory Benford
Tyler Routh is one of 13 leukemia patients who had a remarkable recovery after participating in Dr. Samer Khaled’s CAR T trial.
Will CAR T be the answer for amyloidosis?
May 21, 2019 | Maxine Nunes
A City of Hope scientist believes the solution to the rare disease amyloidosis may be found in one of the most exciting new frontiers of immunotherapy, chimeric antigen receptor T cell therapy.
Bold steps toward a cure: Clinical trials at City of Hope
May 3, 2019 | Abe Rosenberg
City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.
City of Hope launches first CAR T cell trial targeting CS1 protein in multiple myeloma
April 26, 2019 | City of Hope
City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.
Researchers detail new findings at 2019 AACR meeting
March 28, 2019 | Zen Vuong
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Load MoreBack To Top